CJC-1295 (No DAC) + Ipamorelin Blend — 10mg
Research-grade CJC-1295 (No DAC) + Ipamorelin Blend, a dual-pathway growth hormone research complex combining Modified GRF (1-29) (5mg) and Ipamorelin (5mg). Studied for synergistic GHRH/GHS receptor co-activation and amplified pulsatile growth hormone release patterns. 10mg total lyophilized powder, 99%+ purity per component verified by Janoshik Analytical via HPLC and mass spectrometry.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
This blend combines two of the most frequently co-administered peptides in growth hormone research: CJC-1295 (No DAC), a GHRH receptor agonist, and Ipamorelin, a selective ghrelin/GHS receptor agonist. The dual-pathway approach engages both the GHRH axis (upstream stimulation of GH synthesis and release) and the ghrelin axis (amplification of GH pulse amplitude) simultaneously, which published preclinical data suggests produces greater GH elevation than either compound alone. Durham Peptides also carries CJC-1295 (No DAC) and Ipamorelin individually for single-compound research.
BENEFITS
Dual-pathway GH research — GHRH + GHS receptor co-activation in a single vial
Synergistic signaling — published data suggests amplified GH pulse when both pathways are activated concurrently
Pulsatile profile — both components feature short half-lives preserving natural GH secretion patterns
Convenience — eliminates dual-vial reconstitution for combination protocols
Well-characterized components — both peptides have extensive published research individually
WHAT RESEARCHERS LOOK AT
Synergistic GH release: GHRH analog + GHS agonist combination vs. monotherapy
Pulsatile GH secretion patterns in pituitary cell models
IGF-1 downstream effects in combined GHRH/GHS activation
Comparative analysis vs. single-compound administration
Optimal ratios for dual-pathway GH research protocols
